Yes. Ideal Option treats Opioid Use Disorder using FDA-approved partial agonists (Suboxone®, Sublocade®, Brixadi®) and full antagonists (Vivitrol®).

Outpatient medication-assisted treatment (MAT) for prescription opioids, heroin, and illicit synthetics includes:

• Buprenorphine / Naloxone (Suboxone®): Sublingual daily medication that reduces cravings and blocks withdrawal without producing euphoria.
• Extended-Release Buprenorphine (Sublocade®, Brixadi®): Weekly or monthly subcutaneous injections providing steady therapeutic plasma levels.
• Extended-Release Naltrexone (Vivitrol®): Monthly injection blocking opioid receptors for patients who are fully detoxed.

Evidence & Authoritative Reference: The U.S. Food and Drug Administration (FDA) and SAMHSA classify buprenorphine and extended-release buprenorphine formulations as first-line maintenance medications for OUD due to their proven safety profile and lower risk of respiratory depression (FDA Information on Buprenorphine).

Ideal Option treats fentanyl use through specialized induction protocols—including conventional, low-dose (micro-dosing), and high-dose initiation strategies—to transition patients safely onto buprenorphine.

Because illicit fentanyl is highly lipophilic and lingers in fat tissues, standard medication inductions can trigger severe precipitated withdrawal. Ideal Option providers evaluate each patient's timeline and drug exposure to select the safest induction pathway.

Yes. Ideal Option manages alcohol withdrawal and relapse prevention using FDA-approved non-addictive medications.

Medical care for AUD includes:

• Extended-Release Naltrexone (Vivitrol® / Oral Naltrexone)
• Acamprosate (Campral®)
• Disulfiram (Antabuse®)

Evidence & Authoritative Reference: The National Institutes of Health (NIH) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) emphasize that FDA-approved AUD medications are highly effective at reducing heavy drinking, yet remain significantly underutilized (NIH Alcohol Treatment Guidelines).

Yes. Ideal Option treats methamphetamine addiction using combination medical pharmacotherapy supported by recent clinical studies.

While there is no single FDA-approved medication for stimulant addiction, Ideal Option providers utilize an evidence-based combination of injectable Naltrexone plus oral Bupropion (Wellbutrin®), which has been proven in clinical trials to significantly reduce methamphetamine cravings and use.

Evidence & Authoritative Reference: Research published by the National Institutes of Health (NIH) and NIDA (ADAPT-2 Study) demonstrated that combining extended-release naltrexone and bupropion effectively reduces methamphetamine use in adult patients with moderate-to-severe disorder (NIH ADAPT-2 Study Results).

Yes. Ideal Option provides medical symptom support, harm-reduction care, and behavioral health referrals for cocaine addiction.

Although there are no FDA-approved medications explicitly indicated for cocaine dependence, medical providers utilize medications such as Topiramate or Disulfiram off-label alongside behavioral therapy to help reduce cocaine cravings and prevent relapse.

Yes, through clinical evaluation, outpatient outpatient medical tapering, or inpatient referrals depending on severity.

Because sudden withdrawal from benzodiazepines can cause life-threatening seizures, Ideal Option evaluates each case to determine whether outpatient slow-tapering protocols are safe or if higher-level inpatient medical detox is required before outpatient stabilization.

Yes. Ideal Option offers medical oversight and targeted counseling referrals for Cannabis Use Disorder.

While no FDA-approved medications exist specifically for marijuana addiction, evidence-based adjunct medications like N-Acetylcysteine (NAC) may be prescribed, particularly for adolescents and young adults, to modulate brain glutamate levels and diminish cravings.

Yes. Ideal Option treats Kratom and 7-OH dependence using buprenorphine-based medications (such as Suboxone®) combined with medical monitoring.

Kratom and its concentrated alkaloid derivatives (such as 7-hydroxymitragynine) act as partial agonists on mu-opioid receptors, creating physical dependence and severe withdrawal upon cessation. Buprenorphine stabilizes these receptors, eliminating cravings and withdrawal safely.

Evidence & Authoritative Reference: NIDA and NIH research reports highlight that active compounds in kratom bind to opioid receptors, leading to dependence and withdrawal profiles similar to conventional opioids, which respond effectively to buprenorphine treatment (NIDA Kratom Research Science).

Yes. Ideal Option provides cessation treatment for smoking, smokeless tobacco, and vaping for patients undergoing treatment for another substance disorder.

Cessation care includes FDA-approved medications like Varenicline (Chantix®) and Nicotine Replacement Therapy (NRT) (patches, gums, lozenges).

(Note: Individuals seeking support solely for tobacco cessation are directed to call 1-800-QUIT-NOW).

Yes. Ideal Option specializes in treating polysubstance use with individualized, harm-reduction medical care.

Most individuals seeking addiction care use more than one substance. Ideal Option prioritizes treating the substance posing the highest risk of acute harm or fatal overdose (such as illicit fentanyl), while progressively addressing co-occurring alcohol, stimulant, or sedative use.

Evidence & Authoritative Reference: According to the National Institute on Drug Abuse (NIDA), polysubstance use requires tailored medical strategies that address the overlapping effects of multiple drugs, as combining opioids with stimulants or depressants significantly increases overdose complexity and risk (NIDA Polysubstance Use Research).